TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11773294

Group type: EXPERIMENTAL
Intervention: Methotrexate and fluorouracil (MF)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide and methotrexate (CMF)
Number of subjects: 0

Group type: COMPARATOR
Intervention: CMF plus placebo, CMF plus tamoxifen (TAM), doxorubicin and cyclophosphamide (AC) plus placebo, AC plus TAM
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tamoxifen (TAM)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TAM plus either MF or CMF
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Surgery and chemotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chemotherapy plus TAM
Number of subjects: 0

Group type: COMPARATOR
Intervention: Radiation therapy (XRT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: XRT + TAM
Number of subjects: 0
Study: 9564793

Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide (TAA) 400 microg twice daily
Number of subjects: 121

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 121
Study: 7752836

Group type: EXPERIMENTAL
Intervention: Topical application of Coenzyme Q10 (CoQ10) once a week for 6 weeks
Number of subjects: 10

Group type: COMPARATOR
Intervention: Soybean oil (control)
Number of subjects: 10
Study: 3357071

Group type: EXPERIMENTAL
Intervention: VT‐1 (no uncertainty, prescribed therapy)
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: VT‐2 (no uncertainty, prescribed therapy)
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: VT‐3 (expressed uncertainty, prescribed antibiotics without resolution)
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: VT‐4 (expressed uncertainty, consulted reference book, then prescribed)
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: VT‐5 (expressed uncertainty, checked computer, then prescribed)
Number of subjects: 304
Study: 31332977

Group type: EXPERIMENTAL
Intervention: Daily vacuuming of mattresses for 2 weeks
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (cleaned rooms without vacuuming mattresses)
Number of subjects: 40
Study: 29132336

Group type: EXPERIMENTAL
Intervention: Zhang's dynamic guideline for labor progression
Number of subjects: 6582

Group type: COMPARATOR
Intervention: 4-h action line guideline for labor progression
Number of subjects: 6582
Study: 25636601

Group type: EXPERIMENTAL
Intervention: P/T[-] beverage (amino acid beverage deficient in phenylalanine and tyrosine)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: P/T[-] beverage
Number of subjects: 16
Study: 23743404

Group type: EXPERIMENTAL
Intervention: Sapropterin (10 mg/kg)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Local BH4 administration
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 21508092

Group type: EXPERIMENTAL
Intervention: Vitamin C and vitamin E supplementation (n = 14)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo (n = 14)
Number of subjects: 28
Study: 19455068

Group type: EXPERIMENTAL
Intervention: Exemestane
Number of subjects: 135

Group type: COMPARATOR
Intervention: Letrozole
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Diary and event button measures
Number of subjects: 135
Study: 16364159

Group type: EXPERIMENTAL
Intervention: Roflumilast 500 microg once daily
Number of subjects: 499

Group type: COMPARATOR
Intervention: Beclomethasone dipropionate (BDP) 200 microg twice daily (400 microg/day)
Number of subjects: 499
Study: 15243285

Group type: EXPERIMENTAL
Intervention: Transdermal 17beta‐estradiol (50 microg/day) and nomegestrol (5 mg/day for 12 days/month)
Number of subjects: 44

Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Transdermal 17beta‐estradiol and nomegestrol (HT)
Number of subjects: 44
Study: 10654500

Group type: COMPARATOR
Intervention: Propranolol (20 mg four times daily)
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: Propranolol + Magnesium (18 g over 24 hours)
Number of subjects: 167
Study: 9059558

Group type: EXPERIMENTAL
Intervention: recombinant human GH (rhGH) 12 IU/day s.c. for 7 days, followed by salmon calcitonin (sCT) 50 IU/day s.c. for 21 days
Number of subjects: 30

Group type: COMPARATOR
Intervention: placebo for 7 days, followed by salmon calcitonin (sCT) for 21 days
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: recombinant human GH (rhGH) for 7 days, followed by placebo for 21 days
Number of subjects: 30
Study: 8356371

Group type: EXPERIMENTAL
Intervention: 200 mg ketoprofen controlled release (morning dose)
Number of subjects: 163

Group type: COMPARATOR
Intervention: 200 mg ketoprofen controlled release (evening dose)
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Both morning and evening doses of ketoprofen
Number of subjects: 163
Study: 3301990

Group type: EXPERIMENTAL
Intervention: Postcard reminder
Number of subjects: 540

Group type: COMPARATOR
Intervention: Control group (no postcard reminder)
Number of subjects: 540

Group type: EXPERIMENTAL
Intervention: Clinic visit during autumn months
Number of subjects: 540

Group type: EXPERIMENTAL
Intervention: No clinic visit during autumn months
Number of subjects: 540
Study: 31948454

Group type: EXPERIMENTAL
Intervention: Jump Start intervention
Number of subjects: 658

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 658
Study: 28833181

Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Microdebrider-assisted inferior turbinoplasty
Number of subjects: 72

Group type: COMPARATOR
Intervention: Sham surgery
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Active treatment procedures (radiofrequency ablation, microdebrider-assisted inferior turbinoplasty)
Number of subjects: 72
Study: 27898428

Group type: EXPERIMENTAL
Intervention: Very Low-Calorie Diet (VLCD) for 3 months
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Weight maintenance phase after VLCD
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lean control group
Number of subjects: 0
Study: 24405854

Group type: EXPERIMENTAL
Intervention: Structured education intervention incorporating training in self‐monitoring of blood glucose (SMBG) or urine glucose (SMUG)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Training for educators
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Commitment to unbiased delivery
Number of subjects: 39
Study: 22543555

Group type: EXPERIMENTAL
Intervention: Neurocognitive and perceptive rehabilitation treatment (TG)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Common physical therapy (CG)
Number of subjects: 14
Study: 20861328

Group type: EXPERIMENTAL
Intervention: Mtb72F/AS02(A) (10 μg antigen)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Mtb72F/AS02(A) (40 μg antigen)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Mtb72F/AS02(A) (10 or 40 μg antigen)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Mtb72F/AS02(A)
Number of subjects: 50

Group type: COMPARATOR
Intervention: AS02(A) alone
Number of subjects: 50
Study: 18384663

Group type: EXPERIMENTAL
Intervention: 20‐mg rabeprazole once daily for 4 weeks
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 20‐mg rabeprazole once daily for 8 weeks
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Proton pump inhibitors (PPIs)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Erosive oesophagitis (EO) patients
Number of subjects: 40
Study: 16500951

Group type: EXPERIMENTAL
Intervention: BiPAP ventilation
Number of subjects: 20

Group type: COMPARATOR
Intervention: IPPV with or without PEEP
Number of subjects: 20
Study: 15173856

Group type: EXPERIMENTAL
Intervention: Low carbohydrate (CHO), high monounsaturated fatty acid (MUFA), and high fibre feed
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard composition feeds
Number of subjects: 20
Study: 10786750

Group type: EXPERIMENTAL
Intervention: Magnesium (4 mmol)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 30
Study: 9157585

Group type: EXPERIMENTAL
Intervention: r-VIII SQ
Number of subjects: 36
Study: 8363291

Group type: EXPERIMENTAL
Intervention: 200mg of caffeine
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 12.5mg of timolol (2.5mL of timolol 0.5% ophthalmic solution)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Combination of caffeine and timolol
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Wrist rest
Number of subjects: 14
Study: 3302082

Group type: EXPERIMENTAL
Intervention: Transverse colostomy followed by resection with anastomosis (Group T)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Immediate resection with end colostomy and mucous fistula (Group R)
Number of subjects: 55
Study: 30982378

Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 mg twice daily plus MTX
Number of subjects: 0

Group type: COMPARATOR
Intervention: Adalimumab 40 mg every 2 weeks plus MTX
Number of subjects: 0
Study: 28280092

Group type: EXPERIMENTAL
Intervention: Enzalutamide monotherapy (n = 29)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Enzalutamide in combination with endocrine therapies (n = 70)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Exemestane 50 mg/day given with enzalutamide
Number of subjects: 99

Group type: COMPARATOR
Intervention: Exemestane 25 mg/day
Number of subjects: 99
Study: 25577502

Group type: EXPERIMENTAL
Intervention: Exercise intervention
Number of subjects: 19
Study: 23633399

Group type: EXPERIMENTAL
Intervention: chronoFLO4
Number of subjects: 543

Group type: COMPARATOR
Intervention: FOLFOX2
Number of subjects: 543
Study: 21107891

Group type: EXPERIMENTAL
Intervention: Smoke alarms present
Number of subjects: 779

Group type: EXPERIMENTAL
Intervention: Functional smoke alarms
Number of subjects: 779

Group type: EXPERIMENTAL
Intervention: Compliance with functionality and placement recommendations
Number of subjects: 779

Group type: EXPERIMENTAL
Intervention: Post‐1980 constructions
Number of subjects: 779
Study: 19167725

Group type: EXPERIMENTAL
Intervention: Lifting to urinate without a password
Number of subjects: 570

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 570

Group type: EXPERIMENTAL
Intervention: Lifting to urinate with a password
Number of subjects: 570

Group type: EXPERIMENTAL
Intervention: Reward system
Number of subjects: 570
Study: 17472761

Group type: EXPERIMENTAL
Intervention: PSST approach (TAU+PSST+FT)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 82
Study: 14751210

Group type: EXPERIMENTAL
Intervention: Epilepsy surgery
Number of subjects: 20

Group type: COMPARATOR
Intervention: No surgery (control group)
Number of subjects: 20
Study: 11346805

Group type: EXPERIMENTAL
Intervention: Transesophageal echocardiography guided treatment
Number of subjects: 1222

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 1222
Study: 9288409

Group type: EXPERIMENTAL
Intervention: Secobarbital sodium (2.9 mg/kg body weight)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 8506770

Group type: EXPERIMENTAL
Intervention: Antimicrobial prophylaxis (ceftriazone, 1 gr intramuscular)
Number of subjects: 2284

Group type: COMPARATOR
Intervention: Control group (no prophylaxis)
Number of subjects: 2284
Study: 3015654

Group type: EXPERIMENTAL
Intervention: TS stretch reflex
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TA stretch reflex
Number of subjects: 0
Study: 30670840

Group type: EXPERIMENTAL
Intervention: Low-intensity extracorporeal shockwave therapy (Li-ESWT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham control (not yet implemented)
Number of subjects: 0
Study: 28160719

Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT)
Number of subjects: 250
Study: 25957367

Group type: EXPERIMENTAL
Intervention: Imaging-appropriateness guidelines and estimated radiation exposure information
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Estimated radiation information then guidelines
Number of subjects: 0
Study: 23143503

Group type: EXPERIMENTAL
Intervention: Cyclosporine
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Mycophenolate/dexamethasone
Number of subjects: 42
Study: 21765198

Group type: EXPERIMENTAL
Intervention: Stepwise protocol for the treatment of pain (paracetamol, morphine, buprenorphine transdermal patch, pregabaline) for eight weeks
Number of subjects: 352

Group type: EXPERIMENTAL
Intervention: Stepwise protocol for the treatment of pain
Number of subjects: 352

Group type: COMPARATOR
Intervention: Usual treatment (control)
Number of subjects: 352
Study: 19064811

Group type: EXPERIMENTAL
Intervention: ARRIVE trial
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Primary prevention trial in development
Number of subjects: 0
Study: 16859142

Group type: EXPERIMENTAL
Intervention: Intermittent ventilation once every 5 minutes during CPB
Number of subjects: 36

Group type: COMPARATOR
Intervention: No ventilation during CPB
Number of subjects: 36
Study: 12750665

Group type: EXPERIMENTAL
Intervention: 1-phase treatment with bionator
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: 2-phase treatment with headgear/biteplate
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: 2-phase treatment
Number of subjects: 208

Group type: COMPARATOR
Intervention: 1-phase treatment
Number of subjects: 208
Study: 11148916

Group type: EXPERIMENTAL
Intervention: Epileptic patients
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (29 healthy age-matched subjects)
Number of subjects: 32
Study: 8795760

Group type: EXPERIMENTAL
Intervention: Topical verapamil 0.063%, 0.125%, and 0.25%
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Topical verapamil 0.25%
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 1618257

Group type: EXPERIMENTAL
Intervention: Tenoxicam
Number of subjects: 0
Study: 6152055

Group type: EXPERIMENTAL
Intervention: IV alprazolam (1.0 mg)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Oral alprazolam (1.0 mg)
Number of subjects: 6

Group type: COMPARATOR
Intervention: IV and oral alprazolam (1.0 mg)
Number of subjects: 6
Study: 31553712

Group type: EXPERIMENTAL
Intervention: Hypertonic saline injection (experimental neck pain)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Isotonic saline (control)
Number of subjects: 28
Study: 28456615

Group type: EXPERIMENTAL
Intervention: Trabajadora de Salud
Number of subjects: 14

Group type: COMPARATOR
Intervention: Telephone only control group
Number of subjects: 14
Study: 26724641

Group type: EXPERIMENTAL
Intervention: Anastrozole (1 mg/d) plus gefitinib (250 mg/d)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Anastrozole (1 mg/d) plus placebo
Number of subjects: 71
Study: 25358909

Group type: EXPERIMENTAL
Intervention: Low-intensity self-management intervention (4 self-management sessions)
Number of subjects: 228

Group type: COMPARATOR
Intervention: Generic health information (control)
Number of subjects: 228
Study: 22056350

Group type: EXPERIMENTAL
Intervention: Visible RFM
Number of subjects: 49

Group type: COMPARATOR
Intervention: Masked RFM
Number of subjects: 49
Study: 21442588

Group type: EXPERIMENTAL
Intervention: Eagle Tactical Athlete Program (ETAP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Current physical training at Fort Campbell
Number of subjects: 0
Study: 18612534

Group type: EXPERIMENTAL
Intervention: Anticoagulant therapy (specific dosage and duration not mentioned)
Number of subjects: 19274

Group type: EXPERIMENTAL
Intervention: Risk score based on six variables (age >75 years, recent bleeding, cancer, creatinine levels >1.2 mg/dl, anemia, pulmonary embolism)
Number of subjects: 19274
Study: 15701464

Group type: EXPERIMENTAL
Intervention: Home-based exercise training (5 days/week, submaximal bicycle ergometer training, 30 min/day; calisthenics 9 min/day) for 8 weeks
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Home-based exercise training
Number of subjects: 18

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 18
Study: 11835202

Group type: COMPARATOR
Intervention: CFC flunisolide 1000 microg without spacer
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: HFA flunisolide 340 microg with spacer
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: HFA flunisolide 516 microg without spacer
Number of subjects: 12

Group type: COMPARATOR
Intervention: CFC flunisolide
Number of subjects: 12
Study: 10392324

Group type: EXPERIMENTAL
Intervention: Inhaled triamcinolone acetonide (800 mcg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intravenous triamcinolone acetonide (400 mcg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inhaled triamcinolone acetonide (800 mcg) with oral charcoal
Number of subjects: 0

Group type: COMPARATOR
Intervention: All treatments
Number of subjects: 0
Study: 8721464

Group type: EXPERIMENTAL
Intervention: Patient-controlled premedication by i.v. midazolam (mean dose 0.7 mg, 0.7-1.1 mg for anxious patients, 1.7 mg for those using the device)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Fixed dose of 4 mg i.v. midazolam (1-hour infusion)
Number of subjects: 50
Study: 1949366

Group type: EXPERIMENTAL
Intervention: Neoadjuvant CAP plus radiation
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study: 6338996

Group type: EXPERIMENTAL
Intervention: Vertical mattress monofilament nylon sutures
Number of subjects: 341

Group type: COMPARATOR
Intervention: Steel clips which penetrated only the dermis
Number of subjects: 341
Study: 31752850

Group type: EXPERIMENTAL
Intervention: Pitavastatin 1 mg
Number of subjects: 667

Group type: COMPARATOR
Intervention: Pitavastatin 4 mg
Number of subjects: 667
Study: 30058609

Group type: EXPERIMENTAL
Intervention: Procedures for estimating biological occupational exposure limits (BOELs) using regression analysis on 14 organic solvents.
Number of subjects: 14
Study: 26728964

Group type: EXPERIMENTAL
Intervention: Conversational search engine interface (n=43)
Number of subjects: 89
Study: 24217949

Group type: EXPERIMENTAL
Intervention: Yukon-DES (polymer-free sirolimus-eluting stent)
Number of subjects: 701
Study: 22511033

Group type: EXPERIMENTAL
Intervention: Internet-based behavioral pain management intervention
Number of subjects: 26
Study: 19393473

Group type: EXPERIMENTAL
Intervention: Pamidronate, 1 mg/kg, perioperatively and then at 1, 4, 8, and 12 months
Number of subjects: 93

Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Pamidronate
Number of subjects: 93
Study: 17967593

Group type: EXPERIMENTAL
Intervention: Home-based exercise program
Number of subjects: 173

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 173
Study: 15341354

Group type: EXPERIMENTAL
Intervention: Er:YAG laser (160 mJ/pulse, 10 Hz)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Ultrasonic instrument (UI)
Number of subjects: 20
Study: 11070961

Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 57

Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Both
Number of subjects: 57
Study: 9060896

Group type: EXPERIMENTAL
Intervention: Low energy endocavitary cardioversion during exercise
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Low energy endocavitary cardioversion at rest
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: First shock sequence
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Second shock sequence
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Discomfort score at rest
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Discomfort score during exercise
Number of subjects: 16
Study: 8397999

Group type: EXPERIMENTAL
Intervention: One pill each day for < or = 63 weeks
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Electronic monitoring
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Early changes in compliance
Number of subjects: 19
Study: 3522347

Group type: EXPERIMENTAL
Intervention: Potassium chloride treatment
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 2853038

Group type: EXPERIMENTAL
Intervention: Melatonin 100 mg
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Melatonin 1 mg
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 31392960

Group type: EXPERIMENTAL
Intervention: sNEP levels in HFpEF patients
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: sNEP levels in HFpEF patients after adjustment
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: sNEP levels in propensity matched cohorts
Number of subjects: 242
Study: 29984564

Group type: EXPERIMENTAL
Intervention: Aquatic physical training (APT) performed twice a week for 16 weeks
Number of subjects: 54

Group type: COMPARATOR
Intervention: 16 weeks of detraining after APT
Number of subjects: 54
Study: 28807403

Group type: EXPERIMENTAL
Intervention: Hyperuricemia in HFrEF patients
Number of subjects: 324

Group type: EXPERIMENTAL
Intervention: Hyperuricemia in HFpEF patients
Number of subjects: 324

Group type: EXPERIMENTAL
Intervention: Congestion score ≥3 in HFrEF patients
Number of subjects: 324
Study: 26255288

Group type: EXPERIMENTAL
Intervention: Soccer training (SOC, n = 21)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Control group (C, n = 20)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Moderate‐intensity swimming (MS, n = 21)
Number of subjects: 83

Group type: COMPARATOR
Intervention: High‐intensity intermittent swimming (HS, n = 21)
Number of subjects: 83
Study: 23212605

Group type: EXPERIMENTAL
Intervention: Childhood Cancer Survivor Study Needs Assessment Questionnaire (CCSS‐NAQ)
Number of subjects: 1178
Study: 21562755

Group type: EXPERIMENTAL
Intervention: Prednisolone 7.5 mg once daily
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Prednisolone 30 mg once daily
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 19017423

Group type: EXPERIMENTAL
Intervention: Plant stanol ester spreads
Number of subjects: 21
Study: 17052967

Group type: EXPERIMENTAL
Intervention: G-CSF during radiotherapy (group B)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Radiotherapy alone (group A)
Number of subjects: 10
Study: 14749930

Group type: EXPERIMENTAL
Intervention: Combined exposure to noise and whole-body vibration (high intensity: 86 dB(A)/2.5 m/s2)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: High intensity group (86 dB(A)/2.5 m/s2)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Low intensity (77 dB(A) noise and 1.0 m/s2 vibration) and medium intensity (81 dB(A)/1.6 m/s2)
Number of subjects: 54
Study: 10654491

Group type: EXPERIMENTAL
Intervention: Drew‐Anderson Technique (bilateral extracorporeal circulation using patient's lung as oxygenator)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Standard cardiopulmonary bypass procedure (control group)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Drew‐Anderson Technique
Number of subjects: 30